Focus on Urologic Cancers

What’s new in prostate Ca tests: Markers, imagingIn this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Biomarkers for bladder cancer: Current and futureThe role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.